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ABSTRACT
Introduction: TP53 mutations are considered to be the driving factor in the 
initiation of esophageal adenocarcinoma (EAC). However, the impact of this gene and 
its encoded protein as a prognostic marker has not been definitely established yet.
Methods: In total, 204 chemoradiotherapy (CRT)-naive patients with EAC were 
included for p53 protein expression evaluation by immunohistochemistry (IHC) on 
the resection specimens, categorized as overexpression, heterogeneous or loss of 
expression, and correlated with disease free survival (DFS) and overall survival (OS) 
using multivariable Cox regression analysis. In a subset representing all three IHC 
subgroups mutational status of selected candidate genes (n=33) and high throughput 
methylation profiling (n=16) was assessed.
Results: Compared to heterogeneous p53 expression, loss and overexpression 
were both independently predictive for adverse DFS and OS. TP53 mutational status 
significantly correlated with the IHC categories (p=0.035). Most of the EAC with 
loss- or overexpression harbored TP53 mutations (18/20, representing nonsense 
and missense mutations respectively). In contrast, 6/13 EAC with heterogeneous 
expression were TP53 wild type, of which two demonstrated MDM4 or MDM2 
amplification. Combined genomic hypomethylation and high frequency of intra-
chromosomal breaks was found in a selection of EAC without p53 overexpression.
Conclusion: P53 expression pattern is prognostic for DFS and OS in this historical 
cohort of CRT-naive EAC. P53 IHC is an informative readout for TP53 mutational status 
in EAC with either loss- or overexpression, but not in case of a heterogeneous p53 
pattern. Different EAC pathogenesis might exist, related to p53 and other candidate 
gene status, DNA hypomethylation and intrachromosomal breaks.
INTRODUCTION
Esophageal adenocarcinoma (EAC), being rare 
before the second half of the 20th century, is nowadays 
the predominant histological type of esophageal cancer 
in Western countries [1–3]. Presently the prognostication 
of patients with EAC is largely based on the TNM-
classification supplemented with histological criteria [4]. 
Although this system has its value in the stratification 
of patients into prognostic groups [5], the outcome for 
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 61), pp: 104123-104135
                                                     Research Paper
Oncotarget104124www.impactjournals.com/oncotarget
an individual patient is still difficult to predict. This is 
demonstrated by the fact that up to 27% of the patients 
with stage IB develop disease recurrence while up to 
24% of the patients with stage IIIA EAC will have no 
disease recurrence after intentionally curative surgery 
[5]. Therefore, prognostic biomarkers complementing the 
TNM classification are urgently needed.
The TP53 gene (OMIM# 191170), first discovered 
more than 30 years ago, has a cell- and context dependent 
biological function. It has been reported that p53 is 
deregulated in most cancer types. Given its central role 
in the control of proliferation and senescence, it can be 
assumed to be the driving force of cancers of various 
types, including EAC [6–8]. Several types of stress can 
lead to p53 dysregulation. In EAC, mutations in TP53 
are detected early in the pathogenesis, likely linked to 
severe DNA damage in Barrett esophagus (BE) due to 
the reflux of mixed gastric and duodenal juice into the 
esophagus [9]. Recent genome wide studies proposed 
that EAC precursor lesions containing TP53 mutations 
rapidly develop extensive chromosomal instability with 
subsequent oncogene activation [10–12].
Because of its dominant role in the development 
of EAC, p53 was also tested as a biomarker in EAC 
precursor lesions and in advanced EAC. There is growing 
evidence that p53 overexpression is related to dysplasia 
and independently predictive for progression in BE 
[13–18]. Overexpression is likely due to TP53 mutations 
which stabilize the affected protein. “Absence” of p53 
staining was described more recently in dysplastic 
BE [19]. This loss of expression is likely to be related 
to truncating mutations or to alternative, including 
epigenetic, mechanisms. Supporting the significance of 
the loss of expression, a recent IHC p53 study on a large 
prospective BE cohort revealed a significantly higher rate 
of progression to high grade dysplasia or EAC in low 
grade dysplasia harboring p53 overexpression and even 
higher in BE with absence of p53 expression [13].
In parallel to the EAC precursors, the results of 
the earlier investigations also suggested significance of 
p53 in relation to prognosis in advanced EAC [20–22]. 
However, strong conclusions cannot be drawn because 
of several limitations, including heterogeneity related to 
p53 IHC interpretation and patient selection. This may 
have influenced the outcome of these studies and as such 
the true biological effect of p53 in the context of disease 
progression may remain unidentified.
Therefore, the aim of this study was to examine the 
prognostic value of p53 in a well-defined group of chemo- 
and radio-therapy-naive EAC, using a validated IHC 
approach. To further investigate the putative mechanism(s) 
involved, a combinatory investigation of expression 
pattern, mutational status of TP53 and a selection of other 
(relevant) genes, as well as high throughput profiling was 
performed in a subset of EAC.
RESULTS
Patient characteristics
Two hundred and sixteen (216) patients were 
initially identified to be eligible for this study. Of 12 
patients, the formalin-fixed paraffin-embedded (FFPE) 
blocks could not be retrieved and were therefore excluded. 
From the remaining 204 patients with EAC the majority 
had a pT3-tumor (85.3%), tumor positive lymph nodes 
(79.4%) and negative resection margins (62.7%). Detailed 
patient and tumor characteristics are shown in Table 1  and 
Supplementary Table 1.
P53 expression correlates with overall - and 
disease free survival
The optimal cut-off for p53 expression was 
calculated, based on the receiver operating characteristics 
(ROC) curve and Youden-index (see Supplementary 
Table 2 and Supplementary Figure 1), into three groups, 
namely loss of expression (0% of tumor cells positive), 
heterogeneous expression (1-60% of tumor cells positive) 
and overexpression (61-100% of tumor cells positive). The 
interobserver variation for the assessment of p53 between 
the two observers was excellent (kappa 0.850, p<0.001). 
From the 204 patients, 55.9% (n=114) of the EAC showed 
overexpression, 26.5% (n=54) loss of expression, while 
17.6% (n=36) had a heterogeneous expression. In all cases 
this was a homogeneous expression pattern throughout 
the cancer, of which representative examples are shown 
in Figure 1.
The pattern of p53 expression associated with 
disease free survival (DFS); overexpression - median 
DFS 14.6 months (95% CI 10.0-19.2), loss of expression 
- median DFS 14.2 months (95% CI 7.9-20.5) compared 
to the group with heterogeneous p53 expression - median 
DFS 37.1 months (95% CI 24.3-49.9). The corresponding 
Kaplan-Meier curves are shown in Figure 2.
Univariable analysis demonstrated a correlation 
between p53 expression and DFS (p=0.036). The risk of 
recurrence of EAC was increased for patient with p53 
overexpression (hazard ratio (HR) 1.91; 95% CI 1.16-
3.14) as well as loss of p53 expression (HR 1.57; 95% 
CI 0.9-2.74) compared to heterogeneous p53 expression. 
This was also significant after multivariable analysis, 
adjusted for pT-stage, pN-stage, tumor differentiation 
and resection margin status (p=0.001). Patients with p53 
overexpression/loss showed a significantly worse DFS 
compared to heterogeneous expression (HR 2.61; 95% 
CI 1.57-4.32; p= <0.001 and HR 2.75; 95% CI 1.55-4.9; 
p= <0.001, respectively) (Table 2 and Supplementary 
Table 3). A shorter overall survival (OS) was associated 
with p53 overexpression (median OS 19.4 months 
(95% CI 14.3-24.5)), and loss of expression (median 
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Figure 1: Examples of p53 expression in esophageal adenocarcinoma. (A) overexpression (61-100% positive tumor cells) (B) 
heterogeneous expression (1-60% positive tumor cells) and (C) loss of expression (0% positive tumor cells). Magnification 1:100.
Table 1: Clinico-pathological characteristics for the 204 included patients with esophageal adenocarcinoma
All patients n=204 p53 Loss (0%) 
n=54
p53 Heterogeneous (1-
60%) n=36
p53 Overexpression 
(61-100%) n=114 p-value
N % N % N % N %
Age at surgery 
Median 64.0 63.0 68.5 64.0 0.462
Range (IQR) 55.3-72.0 55.0-72.0 56.3-74.0 55.0-72.0
Sex
Male 174 85.3 51 25.0 29 14.2 95 46.6 0.337
Female 30 14.7 5 2.5 7 3.4 17 8.3
Siewert classification
Type 1 75 36.8 23 11.3 11 5.4 41 21.1 0.576
Type 2 129 63.2 33 16.2 25 12.3 71 34.8
Pathologic T-stage 
pT2 27 13.2 9 4.4 3 1.5 16 7.8 0.556
pT3 or pT4 177 86.8 47 23.0 33 16.2 96 47.1
Pathologic N-stage 
pN0 42 20.6 16 7.8 5 2.5 22 10.8 0.207
pN1 or more 162 79.4 40 19.6 31 15.2 90 44.1
Histology grade 
Well 5 2.5 3 1.5 1 0.5 1 0.5 0.498
Moderate 80 39.2 22 10.8 15 7.4 43 21.1
Poor 119 58.3 31 15.2 20 9.8 68 33.3
Resection margin status 
pR0 128 62.7 33 16.2 22 10.8 73 35.8 0.714
pR1 76 37.3 23 11.3 14 6.9 39 19.1
Alive after 60 months 
Yes 34 16.7 10 4.9 8 3.9 16 7.8 0.518
No 170 83.3 46 22.5 28 13.7 96 47.1
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OS 18.5 months (95% CI 15.3-21.7)) compared to the 
group with heterogeneous expression (median OS 32.4 
months (95% CI 23.0-41.8)). Although no significance 
was identified in the univariable analysis (p=0.265), the 
multivariable analysis demonstrated that p53 expression 
was significantly associated with OS (p=0.003). 
Overexpression and loss of p53 expression were 
prognostic for a shorter survival period (HR respectively 
1.99; 95% CI 1.29-3.07; p=0.002 and 2.17; 95% CI 1.33-
3.55; p=0.002) compared to heterogeneous expression 
(Table 2 and Supplementary Table 3).
Targeted mutational analyses and high 
throughput methylation profiling
To shed light on the possible mechanism(s) 
underlying the p53 staining patterns, sequencing of the 
whole TP53 gene was performed using the Ion Torrent 
platform on 33 selected EAC (10 with overexpression, 
10 with loss, and 13 with a heterogeneous expression) 
(Supplementary Table 4). Overall, 25 of 33 (76%) 
EAC showed a TP53 mutation. TP53 status correlated 
significantly with the IHC staining pattern (p=0.035) 
(Figure 3 and Supplementary Table 5). Of the 10 cases 
with loss of expression eight had non-sense mutations 
(splice site, frameshift mutation or stopgain) and two 
no mutation. All EAC with overexpression of p53 as 
detected by IHC had missense mutations. The EAC within 
the heterogeneous p53 expression group demonstrated a 
mixed picture, representing the three different patterns. 
Those with more than 40% p53 positive tumor cells all 
showed missense mutations (n=3), in analogy to EAC 
with overexpression, while in the lower percentage 
category two out of four showed a nonsense mutation (one 
containing both a splice site and stopgain mutation). EAC 
cases with heterogeneous p53 expression in the middle 
group (n=6, 21-40%) demonstrated no underlying TP53 
mutations in four and two nonsense mutations. Besides 
TP53, in total, 21 other proven pathogenic mutations in the 
following genes SMAD4 (n=7), ARID1A (n=5) , PIK3CA 
(n=2), DOCK2 (n=6) and ELMO (n=1) were detected, 
significantly more in EAC with a heterogeneous p53 
Figure 2: Kaplan-Meier curve for disease free survival in chemoradiotherapy-naive patients with esophageal 
adenocarcinoma. Expression pattern of p53 is subdivided into three groups: 0% of the tumor cells positive (loss of expression), 1-60% of 
the tumor cells positive (heterogeneous expression) and 61-100% of the tumor cells positive (overexpression). The dotted line indicates the 
median survival for each of the three groups. Number of patients at risk is indicated for each of the three groups at the bottom of the figure.
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expression (13/21; p=0.032) (Figure 3 and Supplementary 
Table 5). In these samples no mutations in CDKN2A were 
detected. Four cases of our series revealed no mutation in 
the investigated genes (cases 21, 22, 28 and 29). Multiple 
mutations were identified (including TP53) in 15 EAC, 
predominantly again in the heterogeneous p53 expression 
group (9/13 versus 3/10 and 3/10, respectively). In 
addition, a subset of these EAC (n=16) were investigated 
using high throughput methylation profiling for the 
detection of chromosomal alterations between the three 
Table 2: Multivariable Cox regression analysis for disease free survival and overall survival in patients with 
esophageal adenocarcinoma
Multivariable Cox regression analysis
Disease free survival Overall survival
HR 95% CI p-value HR 95% CI p-value
Age NA NA NA 1.026 1.010-1.042 0.001
pT-stage (ref pT2) pT3/4 2.152 1.156-4.005 0.016 2.010 1.168-3.459 0.012
pN-stage (ref pN0) pN+ 3.445 1.981-5.990 <0.001 2.434 1.560-3.796 <0.001
Differentiation (ref good to moderate) 
poor 1.467 1.016-2.119 0.041 1.551 1.112-2.165 0.010
Resection margin (ref pR0) pR+ 1721 1.192-2.484 0.004 1.716 1.230-2.393 0.001
p53 (ref heterogeneous) loss of 
expression overexpression
2.754
2.605 1.547-4.903 1.571-4.320 0.001
* 2.174
1.989
1.333-3.546
1.288-3.071 0.003
*
HR=Hazard Ratio, CI=Confidence Interval, NA = not available, excluding patients who died within one month after 
surgery. P53 expression, based on immunohistochemical expression, was classified as loss of expression (0% of the tumor 
cells positive), heterogeneous expression (1-60% of the tumor cells positive) and overexpression (61-100% of the tumor 
cells positive). *global p-value
Figure 3: Molecular profile of esophageal adenocarcinoma. Mutational profile, as detected by targeted sequencing in 33 cases is 
categorized by p53 expression pattern. The order of samples is determined by the percentage of positive p53 tumor cells. The exact mutations 
found are displayed in Supplementary Table 4, ordered by case number. The CpG methylation-derived information (copy numbers, hypo-
methylation status and relative high frequency breaks are summarized here. Further details are provided in the Supplementary Figures 2 and 3.
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groups [11], including five with overexpression, five 
with loss and six with a heterogeneous expression, all 
with known TP53 mutational status (see Figure 4). No 
hypermethylation of the promotor region of TP53 was 
detected in any of these EAC, including the two cases 
with loss of p53 expression and wild type (not mutated) 
TP53 (cases 18 and 29). Based on copy number variations 
(CNV) derived from these high throughput methylation 
profiles (see Material and Methods section), regional 
chromosomal amplifications were identified, including 
Figure 4: Unsupervised clustering of CpG methylation of 16 esophageal adenocarcinomas, using top 10,454 differential 
probes, in which every row is a methylation probe and every column is a sample. The corresponding violin plots for all methylation 
probes as well as top 10,454 differential probes are depicted in Supplementary Figure 3. At the top of the image, p53 expression and TP53 
mutational status are indicated for each sample. In the bottom of the image, the deviation of the median number of intra-chromosomal breaks 
(median number of intra-chromosomal breaks are calculated, samples with less breaks are depicted in green, and samples with more breaks 
depicted in red, numbers indicate deviation from median number of intra-chromosomal breaks) as well as the two samples with MDM2 and 
MDM4-amplification are indicated. Five samples with an altered p53 pathway (either TP53 mutations or MDM2/4 amplifications) show extensive 
intra-chromosomal breaks (sample 31, 35, 14, 22 and 21), and only one sample without alteration of the p53 pathway (sample 18) showed 
extensive intra-chromosomal breaks. However none of the six samples (sample number 13, 23, 10, 1, 6 and 17) with a missense mutation showed 
an increase of intra-chromosomal breaks. Increased number of intra-chromosomal breaks correlates to the clustered hypomethylated CpG-sites.
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those encompassing for example MDM2 and MDM4, 
two genes of which amplification is known to be related 
to an alternative inactivation of p53 besides mutations. 
Two EAC showed such an amplification (cases 21 and 
22, for MDM2, confirmed by immunohistochemistry, 
and MDM4, respectively, See Supplementary Figure 
2). No other mutations were identified in these cases, 
and both showed a heterogeneous p53 expression (21-
40% of positive tumor cells) (Figures 3 and 4). Besides 
these specific amplifications, an unsupervised clustering 
of the top 10,454 most differentiating CpG-sites was 
performed (see Figure 4 (heatmap) and Supplementary 
Figure 3 (Violin plots)). No difference was identified for 
the overall methylation distribution between the EAC 
investigated (Supplementary Figure 3, bottom panel), 
while a clear hypomethylation profile was identified for 
the most differentiation CpG-sites in seven EAC out of 
the 16 cases. These included three with absence, three 
with a heterogeneous and one with overexpression of 
p53. Only one showed no TP53 anomaly (case 18, no 
p53 expression), while all others demonstrated either a 
mutation in TP53 itself (three nonsense, one missense), 
or amplification of MDM2 or MDM4. In addition, the 
number of intrachromosomal breaks per individual EAC 
was scored based on the CNV profile (see Supplementary 
Figure 2 and Figure 4). This analysis demonstrated that 
six out of the seven EAC with a hypomethylation profile 
showed a higher number of breaks compared to the group 
median, i.e., indicated in red boxes in Figure 4 (including 
those with the MDM2 and MDM4 amplification), while 
this was observed for only two of the EAC within the 
non-hypomethylated group. These data suggest that there 
is a correlation between p53 status (protein expression, 
mutational profile and MDM2/4 amplification), 
accumulation of other mutations (preferentially in the p53 
heterogeneous staining group), preferential presence of a 
hypomethylated profile in the loss and heterogeneous p53 
group, and occurrence of intrachromosomal breaks.
DISCUSSION
This study primarily aimed to evaluate the relevance 
of p53 IHC for survival of patients with advanced EAC. A 
large, well defined cohort of CRT-naive surgically treated 
EAC was analyzed, and the pattern of p53 expression was 
shown to be significantly correlated with DFS and OS, 
independently from other clinico-pathological parameters 
including tumor stage. In addition, p53 expression patterns 
were correlated with the underlying TP53 mutational 
status and genome wide methylation profile and derived 
information on chromosomal anomalies.
TP53 is one of the driving genes for the progression 
of BE into adenocarcinoma and whole genome sequencing 
studies have detected a high mutation frequency of TP53 
in EAC [12, 23, 24]. Conflicting results have, however, 
been reported so far on TP53 and survival in patients 
with EAC [21, 22, 25–30]. Three previous systematic 
reviews analyzed the current literature and performed 
a meta-analysis of up to 16 different studies, employing 
IHC or sequencing of the TP53 gene [6–8]. Although, 
overall, similar results were reported in all three meta-
analyses suggesting a negative effect of mutated TP53 
on prognosis, the data should be interpreted with caution. 
First of all, many of the earlier studies did not consider 
the bias of patient selection and chemoradiotherapy 
(CRT) treatment [20, 28, 31–33]. Several studies included 
patients who received surgery only as well as patients who 
underwent neoadjuvant treatment or definite CRT. This is 
of importance since p53 might modulate CRT response as 
suggested in earlier studies [20, 31–38]. Another important 
limitation of the published studies is the inconsistent 
methodology for detection and classification of p53 
expression. From five studies using IHC on homogeneous 
EAC cohorts (total 384 patients), with surgery as single 
treatment modality and IHC approach, none qualified 
loss of expression as aberrant [21, 22, 26, 27, 29] (see 
Supplementary Table 6). This is significant since according 
to our interpretation, around 26% of EAC showed loss of 
p53 expression and had significantly worse outcome.
In the present study based on evaluation of EAC 
resection specimens of 204 CRT-naive patients, with 
surgery as single modality, p53 was detected by IHC and 
categorized by experienced observers using optimized cut-
off values. The pattern was classified as heterogeneous, 
overexpression or loss of expression.
Until now it is not clear whether p53 IHC or 
sequencing of TP53 is the most optimal tool to improve 
risk stratification in EAC. Mutational status was suggested 
to be preferable by a recent meta-analysis [7]. Several 
previous EAC studies applied mutational status as single 
read out [20, 22, 31]. The assays used for gene sequencing 
in those older studies are likely to be suboptimal, since the 
TP53 gene was only partly sequenced using PCR-based 
methods, which correlates with the low mutational rate 
(40-50%) [20, 22, 31]. Although the efficacy of the gene 
sequencing techniques improved in recent years, they are 
still more time-consuming, labor intensive and expensive 
compared to IHC. Prediction of mutational status by IHC 
could be an alternative, but the prognostic accuracy might 
depend on the underlying cancer type [39]. To study 
the correlation between protein expression pattern and 
genetic status, a subset of 33 EAC was investigated using 
a targeted next generation sequencing approach. TP53 
mutational frequency rate was 76%, which is comparable 
to the recent investigations using whole genome or 
exome sequencing techniques [23, 24]. TP53 status 
significantly correlated with the defined IHC categories 
(p=0.035). EAC with heterogeneous p53 expression 
was also heterogeneous in terms of the underlying TP53 
status, although it seems to be (again) subdivided into 
three groups, similar to loss of expression, similar to 
overexpression, and the (remaining) intermediate group. 
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Of interest is that most additional mutations in the other 
candidate genes investigated were identified in the group 
with heterogeneous p53 expression, including two cases 
with regional amplifications of MDM2 or MDM4 (Figure 
3). These were identified in EAC without any other 
mutation. In contrast, all EAC with high percentage of p53 
positive cells (more than 61%, n=10) showed missense 
mutations in TP53, which is in line with results of two 
earlier studies [22, 40]. EAC with loss of p53 expression 
demonstrated predominantly nonsense mutations, 
including splicing, stopgain and frameshift mutations 
(8/10). These nonsense mutations were also observed in 
a subset of EAC with a heterogeneous, but relatively low 
to modest p53 expression, in fact three out of five cases. 
In 4 out of five of the remaining cases no TP53 mutation 
was found. These observations warrant additional studies 
to be performed.
The putative difference in pathogenesis between 
these subgroups is supported by the results of the 
high throughput methylation profiling performed. The 
hypomethylated profile of the most differentiating CpG 
sites combined with a high frequency of intrachromosomal 
breaks was predominantly observed in EAC with loss 
or a heterogeneous p53 pattern (either by a nonsense 
mutation (n=3) or MDM2/4 amplification (n=2)). No 
apparent differences were observed using all CpG targets, 
demonstrating its specificity. EAC with a hypomethylated 
profile showed a higher frequency of intrachromosomal 
breaks, indicative for chromosomal instability. This is in 
line with the recently suggested role of DNA methylation 
as the newly identified guardian of the genome [41]. 
Based on this small subset of patients, these observations 
might be a potential explanation for the differences in 
DFS and OS as found in the present study, which warrants 
further investigations. Besides the prognostic effect of 
p53 expression, our results are clinically important. TP53 
status might be predictive for response to neoadjuvant 
chemotherapy [20, 42]. Clinical trials, such as the 
PANCHO trial, stratified for TP53 status, are underway 
and have completed recruitment [43]. Other studies rely 
on new therapeutic agents created to restore the wild type 
activity of p53, one of the most promising compounds 
being APR-246 [44]. Here we show that if IHC is used as a 
read-out for mutational status, results should be interpreted 
with caution especially in EAC with a heterogeneous p53 
expression. In contrast, EAC with p53 overexpression or 
loss of expression are likely to have an underlying somatic 
mutation and extensive sequencing might not be necessary.
There are some limitations to this study. TP53 
sequencing was done in a single EAC area, and therefore 
potential intratumoral heterogeneity was not accounted for. 
However, this is considered unlikely to play an important 
role, since identical TP53 mutations and homogeneous 
loss of heterozygosity of the TP53 locus were detected 
across separated tumor regions in EAC previously [45], 
and a homogenous IHC was identified in all cases. 
Furthermore, although p53 is stained using a proven 
informative automatic staining system and a standardized 
protocol, the scoring is subjective in nature. However, the 
interobserver variation for p53 IHC was excellent.
In summary, this study leads to various conclusions. 
First of all, we have demonstrated that p53 expression 
pattern is significantly correlated with DFS and OS. This 
finding stresses the biological role of p53 for the prognosis 
of patients with EAC. Secondly, we have shown that IHC 
is a good read out for the presence of TP53 mutations 
mainly in EAC with p53 overexpression and probably 
in EAC with loss of expression but not in EAC with a 
heterogeneous p53 expression. This might be important 
for current and future studies in which patient treatment is 
stratified according to the TP53/p53 status. In addition, our 
study could suggests existence of different pathogenesis of 
EAC, related to the p53 pathway (TP53 mutational status 
and MDM2/4 amplification), with downstream additional 
mutations of other candidate genes, as well as DNA 
methylation alterations and possibly related chromosomal 
instability. Yet, more work needs to be done for accurate 
genetic classification of EAC to fully reveal prognostic 
genetic signatures and involved mechanisms.
MATERIALS AND METHODS
Patient selection
To evaluate the prognostic value of p53 in patients 
with EAC, a cohort of patients who underwent surgery 
with curative intent between 1995 and 2006, without 
prior (neo-)adjuvant treatment, was selected from the 
Department of Surgery at the Erasmus University Medical 
Center (Rotterdam, The Netherlands). All patients had 
pathologically proven pT2-pT4a adenocarcinoma of the 
esophagus or at the gastro-esophageal junction. Only 
patients who were alive one month after surgery were 
included in the analysis to correct for surgical mortality. 
Clinical and pathological data were prospectively 
collected, including anatomical tumor location according 
to Siewert [46], tumor grade, pathological stage, age at 
surgery, comorbidities, OS and DFS. Tumor grading and 
staging was performed according to the TNM system as 
described by the UICC (Union Internationale Contre le 
Cancer, 2009, 7th edition) [4]. Resection margin positivity 
was assessed on tumor cells in the resection margin. To 
ensure reliable classification, all slides were reviewed by 
an experienced GI pathologist (FK or KB) for depth of 
invasion.
The hematoxylin-eosin colored slides from the 
resection specimens were retrieved from the archive of 
the Department of Pathology at the Erasmus University 
Medical Center and a representative slide with EAC was 
selected. The corresponding FFPE block was retrieved and 
serial 4μm sections for IHC and mutational analysis were 
mounted on glass slides.
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Immunohistochemical analysis
The first slide of each selected FFPE block was 
stained for p53, ready to use kit (clone BP53-11, Ventana 
Medical Systems, Roche, Tuscon, AZ, USA). Staining 
was performed using an automated slide staining system 
(BenchMark Ultra, Ventana Medical Systems, Roche, 
Tuscon, AZ, USA), in which the slides were deparaffinized 
prior to the staining procedure and heat induced epitope 
retrieval at 97°C for 8 minutes. The primary antibody was 
incubated for 4 minutes, after which this was visualized 
using Ultraview (Ventana Medical Systems, Roche, 
Tuscon, AZ, USA) and counterstained with hematoxylin.
For optimal interpretation, representative tumor 
samples were evaluated by two experienced gastro-
intestinal (GI) pathologists (KB and FK) with specific 
knowledge on p53, based on earlier published extensive 
IHC studies on EAC and its precursor lesions [13, 42]. 
A tumor sample with known overexpression of p53 was 
placed as positive control on each slide. Furthermore, 
normal tissue surrounding the tumor cells were evaluated 
for their physiological expression of p53, serving as 
internal control for the sample under investigation. If the 
positive control material or internal control was negative 
the slide was disregarded for analysis. The pattern of 
p53 IHC was scored on all tumors cells present on the 
slide, based on the percentage of tumor cells with nuclear 
positivity on a semi-quantitative 7-point scale: 0%, 1-20%, 
21-40%, 41-60%, 61-80%, 81-90% and 90-100% of the 
tumor cells. If the scores of the two pathologists were 
discordant, a third board certified pathologist evaluated 
the slides (MD), after which the final diagnosis was based 
on the consensus of two of the three pathologists. All 
pathologists were blinded for clinical and pathological 
data.
Mutational analysis and high throughput 
methylation profiling
In total 34 EAC, among them 10 with no expression 
of p53, 14 with heterogeneous expression (1-60% of the 
tumor cells positive) and 10 with overexpression (61-
100% positive tumor cells), were selected for targeted 
gene sequencing. Tumor area was manually macro-
dissected from the successive unstained slides, resulting 
in at least 30% tumor cells. DNA was extracted using 
proteinase K and 5% Chelex 100 resin [47]. An Ion 
AmpliSeq custom-made panel was created for selection 
of genes [45]. This consisted of primers for the entire 
TP53 gene supplemented with hotspots or the entire 
genes known to be frequently altered in EAC (ARID1A, 
PIK3CA, APC, DOCK2, ELMO1, CDKN2A and SMAD4) 
[10–12, 23]. Sequencing was performed on the Ion Torrent 
Personal Genome Machine or IonS5 system (Thermofisher 
Scientific, Hemel Hempstead, UK) according to the 
manufacturers protocol. In short, libraries were created 
using the ION AmpliSeq Library Preparation Kit. Template 
was prepared using the Ion Onetouch Template Kit and 
sequencing was performed with the Ion Sequencing 
Kit as described [47]. One sample was excluded from 
further analysis because of poor DNA quality and high 
frequencies of formalin artefacts. All other samples 
showed comparable and reliable sequence read coverage 
independent from sample age. The sequence variants with 
a read frequency of less than 5% (homozygous reference) 
or more than 95% (homozygous non-reference), with an 
amplicon coverage of less than 50, or a variant coverage 
of less than 10 reads were excluded from analysis, to 
eliminate formalin artefacts. All variants found in an 
intronic, intergenic, non-coding RNA or UTR3/5 region, 
and synonymous single nucleotide variations (SNV) were 
excluded.
Sixteen EAC, among them five tumors with loss 
of expression, five with overexpression and six with 
heterogeneous p53 expression, were selected for genome-
wide methylation analysis in addition to the targeted 
sequencing. Therefore, the Infinium MethylationEPIC 
BeadChip (Illumina, San Diego, CA, USA), targeting over 
850,000 methylation sites, was applied according to the 
manufacturer’s instruction at the Microarray unit of the 
Genomics and Proteomics Core Facility of the German 
Cancer Research Center (DKFZ, Heidelberg, Germany). 
For a detailed description see earlier publication [48]. 
For unsupervised clustering the most differential probes 
(with 0,22 SD difference from the mean) were selected. 
To assess copy number variation (CNV) methylation 
data were implemented in the R/Bioconducter packages 
Conumee. Intra-chromosomal breaks were calculated 
from the number of segments defined by the Conumee 
package (blue horizontal lines in Supplementary 
Figure 3). Segments are defined as chromosomal regions 
with distinct copy number changes to the adjacent region. 
The number of segments relative to the median number 
of segments within this sample series was determined 
for each sample (presented in Figure 4). With this 
method amplification of genes were also assessed as 
described earlier.[49] To validate amplification of MDM2 
immunohistochemistry staining (clone 1F2, Merck 
Milipore, Amsterdam, Holland) was performed on all 
samples in which no TP53 mutation was found.
Ethics
The investigational protocol was approved by the 
medical ethical committee in the Erasmus Medical Center 
(Rotterdam, The Netherlands) (MEC-12-469).
Statistical analysis
The primary endpoint of the study was 5-year 
DFS, defined as the time between surgery and the first 
clinical recurrence of disease, defined as clinical or 
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radiological evidence of disease recurrence. Patients lost 
to follow-up were censored at the time of the last visit 
to the outpatient clinics. Secondary endpoint was OS, 
defined as time between surgery and death. The optimal 
cut-off for IHC was calculated using a ROC-curve and 
corresponding Youden-index (Supplementary Figure 1 and 
Supplementary Table 2).
The interobserver variation for the assessment of 
p53 staining between the two pathologists was calculated 
using Cohen’s kappa. Strength of agreement was 
categorized as follows: 0.00–0.20, poor; 0.21–0.40, fair; 
0.41–0.60, moderate; 0.61–0.80, good; and 0.81–1.00, 
excellent.
Kaplan Meier curves were used to plot the 
5-year DFS by p53 status. Uni- and multivariable Cox 
proportional hazard models were applied to calculate 
the association between p53 IHC and survival. In the 
multivariable analysis adjustments were made for 
all clinical and pathological factors which proved to 
be prognostic for survival in the univariable analysis 
(p<0,05). The pN-stage was dichotomized in pN0 and a 
pN+ (pN1-3) group for the Cox regression analysis. The 
p53 status and mutational status were correlated using 
Fisher’s Exact test. The analysis was performed using 
SPSS-software (version 22, SPSS IBM inc, Armonk, NY, 
USA). A p-value of <0.05 was considered statistically 
significant.
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